Angion Biomedica Corp expected to post a loss of 36 cents a share - Earnings Preview

Elicio Therapeutics

08/11/2022 16:24

* Angion Biomedica Corp  ANGN.OQ   ANGN.O  is expected
to show a
fall in quarterly revenue when it reports  results on November
10 (estimated). 
    * The Uniondale New York-based  company is expected to
report  a
44.1% decrease in revenue to $816.67 thousand from $1.46 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Angion Biomedica
Corp is
for a loss of 36 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Angion
Biomedica
Corp is $1.5​, above​ its last closing price of $0.91. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.43       -0.46      -0.30     Beat    35.3
 Mar. 31 2022  -0.37       -0.43      -0.48     Missed  -10.3
 Dec. 31 2021  -0.66       -0.62      0.58      Beat    193.9​
 Sep. 30 2021  -0.72       -0.72      -0.53     Beat    26.9
 ​​Jun.        -0.69       -0.69      -0.58     Beat    15.6
 30 2021                                                
 Mar. 31 2021  -0.62       -0.62      -1.56     Missed  -150.6
                                                        ​
 Dec. 31 2020  -1.30       -1.30      -1.90     Missed  -46.2
 This summary was machine generated November 8 at 16:24 GMT.  All
figures in US dollars  unless otherwise stated